Evotec (NASDAQ:EVO) Sees Strong Trading Volume - Should You Buy?

Key Points

• Analyst sentiment: Evotec has a consensus rating of Moderate Buy with an average target price of $7.00 (three Buy ratings, one Sell).
• Weak profitability despite revenue: Last quarter Evotec reported $297.02M in revenue and $0.05 EPS but showed a negative net margin (−13.13%) and negative ROE (−12.40%), and analysts forecast a −0.59 EPS for the current year.
• Current trading and technicals: Shares last traded around $3.07 (down ~2.5%) with mid-day volume of 94,956 shares (31% below the prior session); the 50-day and 200-day SMAs are $2.91 and $3.27, respectively.

Shares of Evotec AG (NASDAQ:EVO - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 94,956 shares were traded during mid-day trading, a decline of 31% from the previous session's volume of 138,270 shares.The stock last traded at $3.0660 and had previously closed at $3.23.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on EVO shares. Wall Street Zen upgraded shares of Evotec from a "sell" rating to a "hold" rating in a research report on Saturday, January 10th. HC Wainwright started coverage on shares of Evotec in a research note on Wednesday, April 15th. They set a "buy" rating and a $7.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Evotec in a report on Monday, December 29th. Finally, Berenberg Bank began coverage on Evotec in a report on Tuesday, February 3rd. They set a "buy" rating for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Evotec currently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Evotec Trading Down 2.5%

The company has a 50 day simple moving average of $2.91 and a 200-day simple moving average of $3.27. The company has a quick ratio of 1.99, a current ratio of 2.07 and a debt-to-equity ratio of 0.42.

Evotec (NASDAQ:EVO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The company had revenue of $297.02 million during the quarter. Evotec had a negative net margin of 13.13% and a negative return on equity of 12.40%. Equities analysts predict that Evotec AG will post -0.59 earnings per share for the current year.

Institutional Investors Weigh In On Evotec

A number of large investors have recently bought and sold shares of EVO. Apollon Wealth Management LLC acquired a new position in shares of Evotec during the first quarter valued at about $28,000. BNP Paribas Financial Markets grew its stake in shares of Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after buying an additional 4,600 shares during the period. Bank of America Corp DE increased its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Marshall Wace LLP acquired a new position in Evotec during the 4th quarter worth approximately $40,000. Finally, Thrivent Financial for Lutherans bought a new position in Evotec in the third quarter worth approximately $53,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.